Lyfjathroun Biopharmaceuticals

Lyfjathroun was an Icelandic biopharmaceutical company that specialized in the development of advanced intranasal drug delivery systems. The company's proprietary technology platform utilized absorption enhancers, such as cyclodextrins and chitosan, to facilitate the delivery of both small molecules and large peptides across the nasal mucosa. Their clinical pipeline included nasal formulations of morphine for acute pain, calcitonin for osteoporosis, and insulin for diabetes, designed to offer a non-invasive alternative to parenteral administration. Despite advancing several candidates into Phase 1 and Phase 2 clinical trials, the company eventually ceased operations. Lyfjathroun's research contributed significantly to the field of mucosal drug delivery and the application of cyclodextrins in pharmaceutical formulations.